Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ronald S Go

Showing results (241-250 of 402) with videos related to

Pageof 41
Sort By:
American Journal of Hematology|September 23, 2021
Langerhans cell histiocytosis with lung involvement in isolation and multisystem disease: Staging, natural history, and comparative survivalAntonious Z Hazim, Gordon J Ruan, Marie Hu, et al.
Rheumatology (Oxford, England)|August 26, 2024
Acute kidney injury, an underrecognized feature of VEXAS syndromeKambiz Kalantari, Megan M Sullivan, Loren P Herrera Hernandez, et al.
American Journal of Hematology|April 25, 2017
High prevalence of monoclonal gammopathy among patients with warm autoimmune hemolytic anemiaAishwarya Ravindran, Janani Sankaran, Eapen K Jacob, et al.
Blood|October 13, 2016
The prognostic value of multiparametric flow cytometry in AL amyloidosis at diagnosis and at the end of first-line treatmentEli Muchtar, Dragan Jevremovic, Angela Dispenzieri, et al.
Mayo Clinic Proceedings|August 6, 2019
Etiologies of Extreme Thrombocytosis: A Contemporary SeriesRonan W Hsieh, Aishwarya Ravindran, Christopher C Hook, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 4, 2020
Increased Bone Marrow Plasma-Cell Percentage Predicts Outcomes in Newly Diagnosed Multiple Myeloma PatientsAbdullah S Al Saleh, Harsh V Parmar, Alissa Visram, et al.
British Journal of Haematology|June 13, 2022
Impact of belantamab mafodotin-induced ocular toxicity on outcomes of patients with advanced multiple myelomaJithma P Abeykoon, Julia Vaxman, Sanjay V Patel, et al.
Blood|August 16, 2017
Delineation of the timing of second-line therapy post-autologous stem cell transplant in patients with AL amyloidosisYi L Hwa, Rahma Warsame, Morie A Gertz, et al.
American Journal of Hematology|November 20, 2022
Reduced intensity conditioning allogeneic hematopoietic stem cell transplantation in VEXAS syndrome: Data from a prospective series of patientsAbhishek A Mangaonkar, Kimberly J Langer, Terra L Lasho, et al.
Mayo Clinic Proceedings|May 10, 2017
Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis: The Mayo Clinic ExperienceTaxiarchis V Kourelis, Robert A Kyle, David Dingli, et al.
Pageof 41

Showing results (241-250 of 402) with videos related to

Sort By:
Pageof 41
American Journal of Hematology|September 23, 2021
Langerhans cell histiocytosis with lung involvement in isolation and multisystem disease: Staging, natural history, and comparative survivalAntonious Z Hazim, Gordon J Ruan, Marie Hu, et al.
Rheumatology (Oxford, England)|August 26, 2024
Acute kidney injury, an underrecognized feature of VEXAS syndromeKambiz Kalantari, Megan M Sullivan, Loren P Herrera Hernandez, et al.
American Journal of Hematology|April 25, 2017
High prevalence of monoclonal gammopathy among patients with warm autoimmune hemolytic anemiaAishwarya Ravindran, Janani Sankaran, Eapen K Jacob, et al.
Blood|October 13, 2016
The prognostic value of multiparametric flow cytometry in AL amyloidosis at diagnosis and at the end of first-line treatmentEli Muchtar, Dragan Jevremovic, Angela Dispenzieri, et al.
Mayo Clinic Proceedings|August 6, 2019
Etiologies of Extreme Thrombocytosis: A Contemporary SeriesRonan W Hsieh, Aishwarya Ravindran, Christopher C Hook, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 4, 2020
Increased Bone Marrow Plasma-Cell Percentage Predicts Outcomes in Newly Diagnosed Multiple Myeloma PatientsAbdullah S Al Saleh, Harsh V Parmar, Alissa Visram, et al.
British Journal of Haematology|June 13, 2022
Impact of belantamab mafodotin-induced ocular toxicity on outcomes of patients with advanced multiple myelomaJithma P Abeykoon, Julia Vaxman, Sanjay V Patel, et al.
Blood|August 16, 2017
Delineation of the timing of second-line therapy post-autologous stem cell transplant in patients with AL amyloidosisYi L Hwa, Rahma Warsame, Morie A Gertz, et al.
American Journal of Hematology|November 20, 2022
Reduced intensity conditioning allogeneic hematopoietic stem cell transplantation in VEXAS syndrome: Data from a prospective series of patientsAbhishek A Mangaonkar, Kimberly J Langer, Terra L Lasho, et al.
Mayo Clinic Proceedings|May 10, 2017
Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis: The Mayo Clinic ExperienceTaxiarchis V Kourelis, Robert A Kyle, David Dingli, et al.
Pageof 41